Role of laser therapy in benign prostate hyperplasia (BPH)

Werner T.W. de Riese; Brent A. Sharpe M.D.; David B. Aronoff; Bernhard T. Mittemeyer M.D.

doi:10.1117/12.427807

21 May 2001 Role of laser therapy in benign prostate hyperplasia (BPH)

Werner T.W. de Riese, Brent A. Sharpe M.D., David B. Aronoff, Bernhard T. Mittemeyer M.D.

Proceedings Volume 4244, Lasers in Surgery: Advanced Characterization, Therapeutics, and Systems XI; (2001) https://doi.org/10.1117/12.427807
Event: BiOS 2001 The International Symposium on Biomedical Optics, 2001, San Jose, CA, United States

Abstract

Benign prostatic hyperplasia (BPH) is a common disease in males older than 50 years of age. 75-80% of this population is considered to have some degree of BPH causing clinical symptoms and requiring urological treatment. Transurethral resection of the prostate (TUR-P) is currently the standard surgical treatment modality for BPH. In an attempt to minimize the need for hospitalization and the associated perioperative and postoperative morbidity, alternatives have been sought. Various types of laser techniques such as interstitial laser coagulation and side-firing technology have been proposed. Numerous studies have shown that laser procedures safely and effectively reduce the volume of the prostate. Intra- and postoperative bleeding are nearly unknown complications for laser procedures, whereas this is the most relevant complication for the TUR-P. Due to significant tissue edema after laser treatment, patients commonly show delayed time to void adequately and, therefore, catheter drainage is often necessary for 3 to 21 days. Retrograde ejaculation is reported to occur less (0- 10%) compared to TUR-P (greater than 60%). Urinary tract infections are very common after interstitial laser coagulation. Although not many long-term clinical data are available, various studies have shown that BPH patients improve in symptom score, flow rate and post-void residual up to 3 years after laser treatment. This paper presents a concise review of efficacy, advantages and disadvantages of the most frequently used laser techniques as well as the long-term clinical data compared to TUR-P.

Citation Download Citation

Werner T.W. de Riese, Brent A. Sharpe M.D., David B. Aronoff, and Bernhard T. Mittemeyer M.D. "Role of laser therapy in benign prostate hyperplasia (BPH)", Proc. SPIE 4244, Lasers in Surgery: Advanced Characterization, Therapeutics, and Systems XI, (21 May 2001); https://doi.org/10.1117/12.427807

ACCESS THE FULL ARTICLE

INSTITUTIONAL
Select your institution to access the SPIE Digital Library.

SELECT YOUR INSTITUTION

PERSONAL
Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.

PERSONAL SIGN IN

No SPIE Account? Create one

PURCHASE THIS CONTENT

SUBSCRIBE TO DIGITAL LIBRARY

50 downloads per 1-year subscription

Members: $195

Non-members: $335 ADD TO CART

25 downloads per 1 - year subscription

Members: $145

Non-members: $250 ADD TO CART

PURCHASE SINGLE ARTICLE

Includes PDF, HTML & Video, when available

Members: $17.00

Non-members: $21.00 ADD TO CART

PROCEEDINGS
7 PAGES

DOWNLOAD PAPER SAVE TO MY LIBRARY

GET CITATION

RIGHTS & PERMISSIONS

Get copyright permission Get copyright permission on Copyright Marketplace

KEYWORDS

Laser tissue interaction

Laser therapeutics

Prostate

Fiber lasers

Laser coagulation

Nd:YAG lasers

Laser applications

Show All Keywords

Keywords/Phrases

Search In:

Publication Years